РОЛЬ АНТИБАКТЕРИАЛЬНЫХ ПРЕПАРАТОВ В РАЗВИТИИ СЕРЬЕЗНЫХ НЕЖЕЛАТЕЛЬНЫХ РЕАКЦИЙ У ДЕТЕЙ: АНАЛИЗ РОССИЙСКОЙ БАЗЫ ДАННЫХ СПОНТАННЫХ СООБЩЕНИЙ ArticleТитова А.Р., Асецкая И.Л., Поливанов В.А., Зырянов С.К.Клиническая микробиология и антимикробная химиотерапия. Vol. 19. 2017. P.. 37-37
ASSOCIATION OF OPIOID RECEPTORS GENE OPRM1 POLYMORPHISM AND PHENOTYPIC DIVERSITY OF CHRONIC PAIN SYNDROME OF ONCOLOGICAL GENESIS ArticleBobrova O.P., Shnayder N.A., Zyryanov S.K., Modestov A.A.Медицинская генетика. Vol. 16. 2017. P.. 3-8
ACTUAL QUESTIONS OF TREATMENT OF URINARY TRACT INFECTION IN NEONATES ArticleZyryanov S.K., Shulakova O.A., Gurevich K.G.Качественная клиническая практика. 2017. P.. 46-50
COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS TARGETED THERAPIES IN ADVANCED MELANOMA ArticleKosolapov E.G., Kochenkov F.S., Ziryanov S.K., Gladkov O.A.Качественная клиническая практика. 2017. P.. 12-24
ANALYSIS OF THE STRUCTURE OF CONSUMPTION OF ANTIPLATELET DRUGS IN THE RUSSIAN PHARMACEUTICAL MARKET: 2014-2016 ArticleZyryanov S.K., Dumchenko E.V.Качественная клиническая практика. 2017. P.. 29-34
CLINICAL AND PHARMACOECONOMIC ASPECTS OF ANTI-TNF THERAPY CHANGE FOR MEDICAL REASONS ArticleGushchina U.S., Zyryanov S.K., Orlikhina I.A.Качественная клиническая практика. 2017. P.. 35-42
CYTOKINE GENE POLYMORPHISMS AS PREDICTORS OF CHRONIC PAIN SYNDROME IN ONCOLOGY ArticleBobrova O.P., Shnayder N.A., Petrova M.M., Zyryanov K.S., Sychev D.A.Siberian Journal of Oncology. Vol. 16. 2017. P.. 87-94
FLUOROQUINOLONE USE RESTRICTIONS IN PATIENTS WITH UNCOMPLICATED INFECTIONS AND SAFETY ISSUES ArticleUshkalova E.A., Zyryanov S.K.Клиническая микробиология и антимикробная химиотерапия. Vol. 19. 2017. P.. 208-213
PHARMACOEPIDEMIOLOGICAL STUDY OF THE SAFETY OF DRUG USE IN CHILDREN BY ANALYZING THE RUSSIAN DATABASE OF SPONTANEOUS REPORTS ArticleTitova A.R., Asetskaya I.L., Polivanov V.A., Zyryanov S.K.Качественная клиническая практика. 2017. P.. 43-52
THE TRAINING MANUAL "CLINICAL PROJECT MANAGEMENT" ArticleBelousov D.U., Zyryanov S.K., Kolbin A.S.Качественная клиническая практика. 2017. P.. 80-84
REGULATION OF CONNECTIVE TISSUE DEVELOPMENT BY CALCIUM CHANNEL BLOCKING AGENTS IN ADHESION PROCESS ArticleSKALSKII S.V., SOKOLOVA T.F., ZYRYANOV S.K.Фармакокинетика и фармакодинамика. 2017. P.. 46-50
PHARMACOECONOMIC EFFECTIVENESS OF LENVATINIB IN PATIENTS WITH DIFFERENTIATED RADIOIODINE-RESISTANT THYROID CANCER ArticleZyryanov S.K., D'yakov I.N.Качественная клиническая практика. 2017. P.. 31-37
IMPACT ON THE BUDGET OF ONLS PROGRAM OF VEDOLIZUMAB INTRODUCTION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE ArticleZiryanov S.K., Diakov I.N., Veselov A.V., Kashnikov V.N.Качественная клиническая практика. 2017. P.. 45-52
EFFECT OF GENE POLYMORPHISM OF BIOTRANSFORMATION OF OPIOID ANALGESICS AT PAIN APPRECIATION AND PHARMACOTHERAPY SAFETY ArticleBobrova O.P., Shnaider N.A., Petrova M.M., Zyryanov S.K., Modestov A.A.Анестезиология и реаниматология. Vol. 62. 2017. P.. 468-473
VALUE OF PHARMACOGENETIC MARKERS FOR CLINICAL USE OF MORPHINE IN ONCOLOGY ArticleBobrova O.P., Shnayder N.A., Petrova M.M., Zyryanov S.K.Российский журнал боли. 2017. P.. 95-103